| HOME >> BIOLOGY >> TECHNOLOGY |
We are also building our marketing and product distribution network. Currently, there are about 15 companies participating in the distribution of Gendicine in China.
PARTNERING
BPI: What criteria do you use in selecting
business partners?
Peng: SiBiono has established collaborations with a few domestic and overseas research organizations and universities during Gendicines development period.
We are currently looking for strategic partners. Potential partners include wellknown organizations, foundations, and biotech corporations. We are seeking a partner that, together with SiBiono, can jointly lead and promote worldwide gene therapy development. The partner is expected to collaborate with SiBiono, however; we are not interested in a merger partner. This partner has to be large enough to deal with Chinas huge market.
BPI: Did you have any other consulting help?
Peng: Dr. W. French Anderson, director of the Gene Therapy Laboratories at the University of Southern California and widely considered the father of gene therapy, serves as a free advisor to SiBiono. He plans to visit here once a year in an advisory capacity.
USEFUL REFERENCES
FDA, CBER, Office of Vaccine Research and Review. Points
to consider on plasmid DNA vaccines for preventive
infectious disease indications. 1996 Dec 27. Available
at URL: http://www.fda.gov/cber/gdlns/plasmid.pdf.
FDA,CBER.Biological Response Modifiers Advisory
Committee: July 13, 2001 Transcript. Available at URL:http://www.f
'"/>
Source: